Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.
Revive Completes $1,500,000 Non-Brokered Private Placement
Revive Therapeutics Ltd. Announces US FDA Acceptance of IND of Bucillamine for the Treatment of Cystinuria
Revive Therapeutics Announces New CEO and New President
Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria
Announces $1,500,000 Best-Efforts Non-Brokered Private Placement